New Jersey Assembly members green-lighted an amendment to a psilocybin bill to align its provisions with a Senate companion version from Senate President Nick Scutari (D) that was recently approved by the Senate Health, Human Services and Senior Citizens Committee in a 6–2.
The amendment to the Psilocybin Behavioral Health Access and Services Act from assemblymembers Herb Conaway (D), Clinton Calabrese (D) and Anthony Verrelli (D) was approved by the Assembly Health Committee on Monday, reported Marijuana Moment.
The lawmakers scrapped the bill of language that would more broadly legalize psychedelics. In its current form, the measure is centered around the therapeutic use of psychedelics.
Members of the Massachusetts Senate passed a wide-ranging military veterans-focused measure that seeks to set up a working group tasked with studying and making recommendations around psilocybin and MDMA and their therapeutic benefits, among other things, reported Marijuana Moment.
The psychedelics policy reform provisions were attached to different forms of the Honoring, Empowering and Recognizing Our Service Members and Veterans (HERO Act) in both legislative chambers. The Senate's legislation builds on the legislative package filed by the Healey-Driscoll administration earlier this year.
"We have a responsibility to support and empower every person who has served and sacrificed for our nation once they return home," Senate President Karen E. Spilka (D-Ashland) said in a press release. "We are a Commonwealth that has the deepest respect and gratitude to our veterans, and the HERO Act doubles down on that commitment to our service members by delivering the support that they and their families deserve.
Clinical research firm Alira Health has teamed up with the Scottsdale Research Institute (SRI) to provide regulatory and clinical support to bring clinical research on psilocybin to Arizona.
The new collaboration is aimed at providing strategic guidance and support in regulatory strategy, regulatory submissions, regulatory monitoring, clinical trial design and clinical operations.
If it gets the green light to proceed with testing in human subjects by both the FDA and Arizona State University’s Institutional Review Board (IRB) committee, the Grand Canyon State will be the first one nationwide to host an investigational new drug (IND)-enabled randomized controlled clinical trial using whole mushrooms to administer psilocybin.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code “JAVIER20” for 20% off!